Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.
The COVID-19 pandemic has undoubtedly changed our practice of medicine.
APA
Ali A (2020). Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.. Headache, 60(6), 1183-1186. https://doi.org/10.1111/head.13830
MLA
Ali A. "Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.." Headache, vol. 60, no. 6, 2020, pp. 1183-1186.
PMID
32359098
Abstract
The COVID-19 pandemic has undoubtedly changed our practice of medicine. With our collective resources and attention focused on caring for those afflicted with the disease, other medical conditions have temporarily but understandably faced constraint. For migraine patients who often require in-person visits for infusions and procedures, this has become particularly challenging. Here, we share our experience in navigating this exigency amidst a local surge of COVID-19.
MeSH Terms
Adult; Betacoronavirus; Botulinum Toxins, Type A; COVID-19; Coronavirus Infections; Female; Humans; Middle Aged; Migraine Disorders; Pandemics; Pneumonia, Viral; SARS-CoV-2; Time-to-Treatment; Treatment Outcome
같은 제1저자의 인용 많은 논문 (5)
- Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.
- Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.
- Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate Cancer.
- Cardiorespiratory Fitness and Colorectal Cancer Incidence in US Veterans: A Cohort Study.
- Exploring the therapeutic potential of baicalin against MCF-7 breast cancer cells: biochemical, , and computational perspectives.